Urofollitropin biosimilar - Vitro Diagnostics

Drug Profile

Urofollitropin biosimilar - Vitro Diagnostics

Alternative Names: Vitropin

Latest Information Update: 18 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vitro Diagnostics
  • Class Follicle stimulating hormones; Infertility therapies; Menotropins; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Female infertility

Most Recent Events

  • 18 Aug 2015 Active development is ongoing
  • 28 Aug 2012 Active development is ongoing
  • 28 Aug 2012 Dr James T. Posillico has begun the process of seeking registration of Vitro Diagnostics' urofollitropin for the treatment of female infertility in certain countries external to the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top